In oncology, development decisions carry weight quickly. Many reference products are clinically important, widely used and closely watched by regulators, partners and healthcare systems. That raises the bar for how programs are designed, documented and advanced.
The market context explains part of that pressure. Oncology remains one of the leading therapeutic areas for biosimilars, and the pace of approvals continues to grow. As of July 2025, the FDA had approved 72 biosimilars and the EMA had authorized 119, excluding withdrawn products, with oncology among the main therapy areas represented in the market (Alira Health, 2025).
In practical terms, this means oncology biosimilars development has to do two things at once: demonstrate similarity with rigor and prepare for execution at scale.
The challenge starts with product complexity
Many oncology biologics are sensitive molecules where quality depends heavily on process control. Structural and functional similarity cannot be supported by surface-level characterization. Developers need a deep understanding of critical quality attributes, product variability and analytical performance.
This is one of the points where CDMOs can make a meaningful difference. Strong analytical development helps teams build a more reliable comparability package, reduce uncertainty earlier and support decisions with better data. In oncology biosimilars, that matters because a weak analytical footing creates problems that tend to reappear later.
Manufacturing questions arrive earlier than expected
One of the recurring mistakes in biosimilars development is to think about manufacturing readiness too late. In oncology, that becomes especially risky. A process may look stable during development and still become difficult to scale, transfer or reproduce under GMP conditions.
What makes a difference here is not speed alone. It is whether process development has been built with the next stage in mind. CDMOs help by connecting early development work with later manufacturing requirements: process characterization, scale-up planning, facility fit, tech transfer thinking and quality oversight. That continuity is valuable in any biosimilar program, but in oncology it becomes harder to replace once timelines tighten.
Delays often come from coordination, not science alone
Oncology biosimilars programs are rarely slowed down by one major technical issue in isolation. More often, friction appears between functions: development, analytical, manufacturing, quality, regulatory and external partners moving at different speeds.
This is where an experienced CDMO brings more than capacity. A well-structured model helps keep technical work, documentation and execution aligned across the life of the program. That kind of coordination is easy to underestimate at the beginning and difficult to recover later.
Why this matters beyond development
There is also a broader reason oncology biosimilars deserve this level of attention. They are part of how healthcare systems expand access to high-cost cancer therapies.
Biosimilars generated $20.2 billion in U.S. savings in 2024 alone, according to the Association for Accessible Medicines (2025). In oncology, that impact goes beyond budgets. For example, NHS England reinvested the savings generated by biosimilars into the Cancer Drugs Fund, supporting early access to innovative and promising oncology medicines (Kvien et al., BioDrugs, 2025). That is why development quality matters so much in this space. Better execution upstream can translate into broader access downstream.
A robust workflow for a demanding sector
When companies search for CDMO support in oncology biosimilars, they are usually looking for more than technical execution. They need a partner that can help reduce uncertainty across development and prepare the program for what comes next.
The capabilities that matter most tend to be clear:
- deep analytical expertise
- robust process development
- early manufacturing readiness
- cross-functional coordination
- GMP mindset from the development stage onward
How mAbxience supports this path
At mAbxience, this challenge is approached through an integrated development-to-manufacturing model built around quality, control and readiness. Across our materials, we consistently link biosimilars to broader treatment access, a quality by design mindset and the importance of building robust processes that can progress with confidence toward GMP and commercial manufacturing.
In oncology biosimilars, that approach is especially relevant. Because these programs need to advance on solid ground.
